AnaBios News

News 2017-10-30T22:36:39+00:00

AnaBios Announces the Hire of Dr. Chris Mathes as Chief Commercial Officer

SAN DIEGO, CA – May 22, 2018 – AnaBios is pleased to announce the recent hire of Chris Mathes, Ph.D., MBA, as Chief Commercial Officer. Within this new role, Mathes will guide the company’s business development endeavors and contribute to AnaBios’ overall strategic direction as it leverages its proven drug de-risking technology based on ex vivo human pharmacological responses. Mathes joins AnaBios from early drug discovery company Icagen, where he was Chief Commercial Officer. Prior to that, he served as Chief Commercial Officer at ChanTest, now part of Charles River, and headed up North American business development activities for [...]

May 21st, 2018|

AnaBios Announces Agreement with Sanofi to Develop Atrial Fibrillation Treatment

SAN DIEGO, CA – February 8, 2018 – AnaBios announced today a partnership with Sanofi to develop a new treatment for atrial fibrillation. The program will focus on compounds designed to modulate a novel cardiac ion channel target. Through this agreement, AnaBios will acquire development and commercialization rights to an entire family of promising compounds addressing the global atrial fibrillation market, which is estimated to reach $16.17 billion by 2020 according to a recent report by Grand View Research. “Our new partnership with Sanofi, a global healthcare leader, validates the tremendous accomplishments of AnaBios in developing a human tissue- [...]

February 8th, 2018|

Frontiers in Physiology Publishes Research Showing Pro-Arrhythmia Risk Predictivity of Adult Human Primary Ventricular Tissue-Based Model

SAN DIEGO, CA – January 22, 2018 – First-of-its-kind preclinical ex-vivo human cardiac research conducted by AnaBios and Amgen, published today in the journal Frontiers in Physiology, demonstrates that isolated human heart-based model, combined with the integrated analysis using newly-developed pro-arrhythmic score, can differentiate between pro-arrhythmic and non-pro-arrhythmic compounds and has a greater predictivity when compared to models derived from human stem cells. “Our innovative translational approaches enable human-focused drug discovery and help ensure the safety and efficacy of new treatments,” said Dr. Andre Ghetti, Chief Executive Officer of AnaBios. “Data from this research demonstrates that isolated adult human [...]

January 23rd, 2018|

AnaBios Cardiomyocyte Research Published in “Frontiers in Physiology” Journal

"Frontiers in Physiology," one of the world's leading physiology research journals, published research regarding AnaBios' adult human primary cardiomyocyte-based model that has the potential to predict drug-induced inotropic and pro-arrhythmia risks at the preclinical phase. To view the article, visit the "Frontiers in Physiology" website.

December 20th, 2017|

Pain Research Forum Highlights AnaBios Human DRG Neurons Presentation at Pain and Migraine Therapeutics Summit

The Pain Research Forum highlighted AnaBios CEO Dr. Andre Ghetti's recent presentation at the 11th Annual Pain and Migraine Therapeutics Summit in San Diego, California. Dr. Ghetti discussed the importance of utilizing human DRG neurons early in the drug discovery process to accurately predict human responses to molecular compounds.From the article:The human DRG neurons, Ghetti said, have great predictive value for development of pharmaceutical agents. For example, one compound—an unnamed sodium channel blocker—showed promise in rodents, halting firing of action potentials in DRG neurons and reversing hypersensitivity in vivo. But the compound had no effect on human DRG neurons, even [...]

December 6th, 2017|

AnaBios to Present Adult Human Primary Cardiomyocyte Research on Safety Pharmacology Society Webinar

AnaBios Scientific Director Najah Abi-Gerges, PhD, will present "Adult Human Primary Cardiomyocyotes: An Integrative Translational Model for Cardiotoxicity Assessment" on Thursday, November 2, from 11am-12pm EDT. Drug-induced irregular heart beat (pro arrhythmia) and/or changes in contractility (inotropic liability) can limit the utility of potential novel therapeutics. Since abnormal ventricular repolarization can cause not only electrical disorders, but also affect the heart’s contractile function, the main motivation of this study was to develop a new model based on adult human primary cardiomyocytes to provide a preclinical tool for the simultaneous prediction of drug-induced inotropic and pro-arrhythmia risks. To facilitate the scalability [...]

October 26th, 2017|

A Human Ex-Vivo Contractility-Based Assay for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-Arrhythmia Risk.

Thursday, March 16th from 8:30 am to 11:45 am: "A Human Ex-Vivo Contractility-Based Assay for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-Arrhythmia Risk." Hall A of the Exhibit Hall (Dr. Najah Abi-Gerges). If you will be at the meeting in March, please contact Alisen James:, to let us know. We forward to connecting with both colleagues and clients.  

March 16th, 2017|

​​​​AnaBios to attend the 2017 Society of Toxicology Annual Meeting and Exposition in Baltimore, MD, U.S.A.

Upcoming in March, AnaBios will be presenting and exhibiting at the 2017 Society of Toxicology Annual Meeting and Expo, taking place at the Baltimore Convention Center, March 13th – 16th. AnaBios’ exhibit/booth number is #519.  Dr.’s Paul Miller and Najah Abi-Gerges will be in attendance to discuss the latest in research and service offerings. Poster presentations are as follows:

February 13th, 2017|

AnaBios invited to speak at prestigious Gordon Research Conference in Ventura, CA

AnaBios invited to speak at prestigious Gordon Research Conference in Ventura, CA, February 6th – 10th, 2017. ​​Dr. Najah Abi-Gerges, Scientific Director for AnaBios, has been accepted to speak at The Gordon Research Conference in February 2017, in Ventura, CA. Dr. Abi-Gerges will speak on " “Proarrhythmia Predictions Using Primary Human Cardiomyocytes."   The Gordon Research Conference, founded in 1941, is a prestigious international scientific conference, dedicated to highlighting the latest in cutting-edge research in fields ranging from physics to neurobiology, and material science to medicine. The conference is limited to 200 attendees; all presenters must apply and be [...]

February 6th, 2017|

Program will Accelerate Purdue’s Nav1.7 Sodium Ion Channel Drug Candidates with AnaBios’ Phase-X® Discovery Platform

December 5, 2016: Program will Accelerate Purdue’s Nav1.7 Sodium Ion Channel Drug Candidates with AnaBios’ Phase-X® Discovery Platform Purdue Pharma L.P. and AnaBios Corporation announced today a collaboration to advance the research of non-opioid, non-NSAID compounds for the treatment of chronic pain. The goal of the collaboration is to accelerate Purdue's Nav1.7 sodium ion channel drug candidates utilizing AnaBios' Phase-X® discovery platform to develop treatments for chronic pain.   Under the terms of the agreement, Purdue Pharma will license to AnaBios the rights to a suite of patents for Nav1.7 sodium ion channel blockers. AnaBios will employ its Phase-X® technology [...]

December 5th, 2016|